First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial

Lancet

Volumn 360, Issue 9336, 2002, Pages 817-824

  Cuzick, J ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

AGE; ARTICLE; BREAST CANCER; BREAST DUCT; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; IMMOBILIZATION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 80052059849     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09962-2     Document Type: Article

References (18)

1. Beatson G.W. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 2:1896;104-107.
2. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer. 14:1936;217-225.
3. Pike M.C., Krailo M.D., Henderson B.E., et al. Hormonal risk factors, breast tissue age and the age-incidence of breast cancer. Nature. 303:1983;767-770.
4. Thomas H.V., Key T.J., Allen D.S., et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer. 76:1997;401-405.
5. Cuzick J., Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1:1985;282.
6. Cuzick J., Wang D.Y., Bulbrook R.D. The prevention of breast cancer. Lancet. 2:1986;83-86.
7. Early Breast Cancer Trialists' Collaborative Group . Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
8. Powles T.J., Tillyer C.R., Jones A.L., et al. Prevention of breast cancer with tamoxifen: an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 26:1990;680-684.
9. Powles T.J., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
10. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1387.
11. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 352:1998;93-97.
12. Cuzick J. Chemoprevention of breast cancer with tamoxifen. Hakama M., Beral V., Cuiatti E., Faivre J., Parkin D.M., Chemoprevention in cancer control. IARC Scientific Publication number 136. 1996;95-109 IARC, Lyon.
13. Cuzick J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer. 36:2000;1298-1302.
14. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 65:2001;125-134.
15. National Health Service. Clinical Terms (The Read Codes). London: Stationery Office, 2001.
16. Grady D., Wenger N.K., Herrington D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 132:2000;689-696.
17. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 104:2001;499-503.
18. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 359:2002;2131-2139.